Monteverde & Associates PC, a top-ranked class action law firm, is investigating the sale of Mistras Group, Inc. to affiliates of H.I.G. Capital. The proposed deal offers Mistras shareholders $20.35 per share in cash. The firm is assessing whether this transaction is fair to shareholders and encourages those with concerns or questions to contact them for free legal information. Monteverde & Associates has a strong track record of recovering money for shareholders in securities class actions.
Mistras Group, Inc. is under investigation by a class action firm regarding its sale. For readers following Industrials-sector stocks, here is Pluang's market snapshot as of Sep 21, 2026 18:51 WIB: Out of 80 priced US Industrials stocks, 57 rose and 12 fell. United Airlines Holdings Inc (UAL) rose 2.16% to USD 111.06, Delta Air Lines, Inc. (DAL) rose 2.11% to USD 81.30, and American Airlines Group Inc (AAL) rose 2.08% to USD 13.23. Typical hold times on Pluang range from 45 to 96 days for these movers.
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Piper Sandler lowered Colgate-Palmolive's price target to $95 due to weak North American demand and rising competition. The company is responding by focusing on premium oral care innovations, expanding the Fabuloso line, increasing advertising, and c...
MillerKnoll is set to report Q3 2026 earnings with analysts expecting $0.35 EPS and $940.93 million in revenue. The North America Contract segment shows strength with higher prices and volumes, while the Global Retail segment struggles due to tariffs...
Faruqi & Faruqi, LLP is investigating claims against Ardelyx for allegedly misleading investors about the commercial performance of its drugs XPHOZAH and IBSRELA. The lawsuit alleges Ardelyx failed to disclose increasing payer restrictions that hurt ...
